PCC Rokita SA (PCR) Fair Value & Analysis
Basic Materials · PL · Market cap 1.4B PLN
Fair value as of: Jun 24, 2026
Analysis
PCC Rokita SA (PCR) currently trades at 67.60 PLN, while our model-based Fair Value estimate is 51.59 PLN — implying the stock looks roughly 23.7% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
PCC Rokita SA designs, produces, and sells chemical products in Poland, Germany, the European Union, rest of Europe, the United States, Asia, and internationally. It operates through five segments: Polyurethanes, Chlorine Derivatives, Other Chemical Activities, Energy, and Other Activities. The Polyurethanes segment produces polyols, polyurethane systems, and prepolymers; and flexible foams, rigid foams, coatings, elastomers, adhesives, impregnations, and other products. The Chlorine Derivatives segment provides chlorine, sodium hydroxide, caustic soda, chlorobenzene, and hydrochloric acid. The Other Chemical Activities segment offers phosphorus-derivative and naphthalene-derivative products. The Energy segment produces and distributes electricity, thermal energy, demineralized water, and compressed air. The Other Operations segment is involved in the provision of maintenance services for technological equipment and installations; industrial waste management; hazardous goods transpo…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PCC Rokita SA (PCR) undervalued?
What is the fair value of PCR?
What is the quality score of PCR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.